Core Viewpoint - The approval of the IND for ASC30 by the FDA marks a significant milestone for the company, potentially enhancing its market position in the diabetes treatment sector [1] Company Summary - The company's stock, Gilead Sciences-B (01672), rose over 5%, specifically by 5.21%, reaching HKD 12.12 with a trading volume of HKD 2.7083 million [1] - ASC30, developed by the company, is the first and only small molecule GLP-1 receptor agonist currently in clinical research that can be administered either orally once daily or via subcutaneous injection monthly to quarterly [1] Industry Summary - The Phase II clinical trial for ASC30 is a 13-week, randomized, double-blind, placebo-controlled, multi-center study aimed at evaluating the efficacy, safety, and tolerability of ASC30 in subjects with type 2 diabetes [1] - The primary endpoint of the Phase II study is the average change in glycated hemoglobin (HbA1c) from baseline at 13 weeks, comparing the treatment group to the placebo group [1]
港股异动 | 歌礼制药-B(01672)涨超5% 近期已获FDA批准开展ASC30在糖尿病受试者中的II期研究